Compare Medtronic PLC (MDT) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Nuscale Power Corporation — how do they compare? Medtronic PLC trades at $82.39 (market cap $106.61B), while Nuscale Power Corporation trades at $8.62 (market cap $2.76B). The key difference: Medtronic PLC is far larger — about 38.6× Nuscale Power Corporation's market cap, and Medtronic PLC pays a 3.46% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| MDT | SMR | |
|---|---|---|
Market Cap | $106.61B | $2.76B |
Sector | Health | Utilities |
52-Week High | $105.35 | $53.43 |
52-Week Low | $73.75 | $7.64 |
Enterprise Value | $125.36B | $1.87B |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
SMR (NuScale Power) trades at $7.96, up 3.2% today but remains in a bearish technical trend. The company faces severe financial strain with a net income margin of -2,066.55% and negative cash flow from operations of $459.61M in 2025. Recent earnings misses and high cash burn highlight execution risks, yet analyst consensus suggests 54% upside to a $12.25 price target, with 50% of coverage rating the stock a Buy amid optimism for its small modular reactor technology.
The stock presents a high-risk, high-reward opportunity. Long-term potential hinges on commercializing its nuclear technology, but near-term risks include persistent losses, funding needs, and project delays. Investors must weigh the speculative growth narrative against fundamental weaknesses and high volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
